Verucerfont is acorticotropin-releasing factor receptor 1(CRF1) antagonist withIC₅₀s of ~6.1, >1000 and >1000 nM for CRF1, CRF2, and CRF-BP, respectively.

IC50: 6.1 nM (CRF1), >1000 nM (CRF2), >1000 nM (CRF-BP)^[1]

Post hocanalysis shows that the prototypic non-peptide CRF1 receptor antagonist NBI30775 (R121919) and Verucerfont are both significantly different from vehicle, CP-316 311, and pexacerfont (P<0.001 for all comparisons collapse across time-points); the latter three treatments in turn do not differ from each other. A differential effect of treatments over time is also shown by a significant treatment×time interaction (F[20,140]=6.4, P<0.001). Accordingly, detailedPost hocanalysis shows that both NBI30775 and Verucerfont inhibit ACTH release throughout the following 6 h of measurement (P<0.001 vs vehicle at each time-point, and vs the respective pretreatment baseline)^[1].

406.48

Solid

C₂₂H₂₆N₆O₂

885220-61-1

Room temperature in continental US; may vary elsewhere.

DMSO : 83.33 mg/mL(205.00 mM;Need ultrasonic)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。